The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Two placebo-controlled phase 3 studies of fostamatinib, an oral spleen tyrosine kinase (Syk) inhibitor, for the treatment of persistent/chronic immune thrombocytopenia (ITP) in adults: Analysis of platelet response by prior ITP therapies.
 
James B. Bussel
Consulting or Advisory Role - Amgen; Momenta Pharmaceuticals; Novartis; Protalex; Rigel
Research Funding - Amgen; Novartis; Rigel
 
Donald Arnold
Honoraria - Amgen; Novartis; Rigel
Consulting or Advisory Role - Amgen; Novartis; Rigel; UCB
Research Funding - Bristol-Myers Squibb; Novartis; Rigel
 
Nichola Cooper
Consulting or Advisory Role - Amgen; Novartis
Speakers' Bureau - Amgen; Novartis
 
Alhossain Abdallah
No Relationships to Disclose
 
Michael Boxer
No Relationships to Disclose
 
Darla K. Liles
No Relationships to Disclose
 
Waleed Ghanima
Consulting or Advisory Role - Amgen; Novartis
Speakers' Bureau - Amgen; Novartis; Pfizer
Research Funding - Bayer; Bristol-Myers Squibb; Novartis
 
Keith McCrae
Consulting or Advisory Role - Halozyme
Research Funding - Celgene
 
Hany Zayed
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Sandra Tong
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Ben Cadieux
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Anne-Marie Duliege
Employment - Rigel
Stock and Other Ownership Interests - Rigel